Tanvex BioPharma Inc (6541) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Tanvex BioPharma Inc TWD 4.94, price TWD 30.30, upside -83.7%, quality 18 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Tanvex BioPharma Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 30.30 TWD – 228.00 TWD · fair‑value band 3.69 TWD – 7.37 TWD · the 30.30 TWD price screens above the 4.94 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Tanvex BioPharma in your weekly email
Every Wednesday you see whether Tanvex BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.
Show more
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands.
Stock analysis
Tanvex BioPharma Inc (6541) currently trades at 30.30 TWD, while our model-based Fair Value estimate is 4.94 TWD, implying the stock looks roughly 513.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 3.69 TWD (bear) to 7.37 TWD (bull), the price of 30.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 18/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Tanvex BioPharma Inc reported revenue of 401M TWD in FY2025 versus 5.4M TWD in FY2021, a compound +193.5%/yr. Reported net income was −1.5B TWD in FY2025.
Key figures
Market cap 10.7B TWD (≈ $336M) · P/S ratio 22.1 · EPS (TTM) −6.13 TWD · Net margin −294% · Return on equity −26.1% · Return on assets (EBIT) −44.2% · Operating margin −301% · Revenue (TTM) 484M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 54% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −84%, 6541 screens richer than that median.
Fair Value models
Bear 3.69 TWDFair Value 4.94 TWDBull 7.37 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,056.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+161.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+321.9%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−695,214.0% (2020) → −346.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−84% · Bottom 25%
Profitability
Return on assets−11% · Below median
Growth and dividend
Revenue growth166% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.06× · Cheapest 25%
P/S (TTM)0.70× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Tanvex BioPharma Inc (6541) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4.94 TWD versus a price of 30.30 TWD, about −84% upside (overvalued).
What is the fair value of 6541?
Our model-based fair value for Tanvex BioPharma Inc is 4.94 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 30.30 TWD.
What is the quality score of 6541?
Tanvex BioPharma Inc has a Quality Score of 18/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tanvex BioPharma Inc (6541)?
Our model-based price target is the fair value of 4.94 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 3.69 TWD, optimistic scenario 7.37 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Tanvex BioPharma Inc stock forecast for 2026?
Our models put fair value at 4.94 TWD, about −84% upside versus a price of 30.30 TWD (overvalued). Cautious scenario 3.69 TWD, optimistic scenario 7.37 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Tanvex BioPharma Inc (6541)?
Tanvex BioPharma Inc reported trailing-twelve-month revenue of about 484M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Tanvex BioPharma Inc (6541)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tanvex BioPharma Inc it is 4.94 TWD per share (as of Sep 24, 2026), against a price of 30.30 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Tanvex BioPharma Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6541 trades above its calculated fair value: price 30.30 TWD, fair value 4.94 TWD, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6541?
No. The price is what the market pays today (30.30 TWD); the fair value is what the company's own numbers justify (4.94 TWD). For Tanvex BioPharma Inc the two are 25.36 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Tanvex BioPharma Inc worth?
The market values Tanvex BioPharma Inc at about 10.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 30.30 TWD; our models calculate a fair value of 4.94 TWD per share.
What do the bullish and bearish scenarios say about 6541?
Our models span a range for Tanvex BioPharma Inc: cautious scenario 3.69 TWD, base 4.94 TWD, optimistic 7.37 TWD per share (as of Sep 24, 2026, price 30.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tanvex BioPharma Inc (6541)?
Balance-sheet figures for Tanvex BioPharma Inc (as of Sep 24, 2026): return on equity −26.1%. They feed the Quality Score of 18/100, which measures business quality independently of the share price.
How far is 6541 from its 52-week high?
Tanvex BioPharma Inc trades at 30.30 TWD, about 54% below its 52-week high of 65.30 TWD and at the low of 30.30 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 4.94 TWD is for.
Which stocks are comparable to Tanvex BioPharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tanvex BioPharma Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 30.30 TWD, calculated fair value 4.94 TWD (−84%), Quality Score 18/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6541 calculated?
We run Tanvex BioPharma Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.94 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Tanvex BioPharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tanvex BioPharma Inc (6541)?
The closing price on Sep 24, 2026 was 30.30 TWD. Our model-based fair value is 4.94 TWD, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tanvex BioPharma Inc right now?
The price sits above even our optimistic bull case (7.37 TWD). The favourable scenario is already priced in. Weak quality (18/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.69 TWD to 7.37 TWD) leaves room in how you read the outcome.
Key figures of Tanvex BioPharma Inc
How large is the market capitalisation of Tanvex BioPharma Inc (6541)?
The market capitalisation of Tanvex BioPharma Inc is 10.7B TWD (≈ $336M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tanvex BioPharma Inc (6541)?
The price-to-sales ratio of Tanvex BioPharma Inc is 22.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tanvex BioPharma Inc (6541)?
Earnings per share at Tanvex BioPharma Inc are −6.13 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tanvex BioPharma Inc (6541)?
The net margin of Tanvex BioPharma Inc is −294% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tanvex BioPharma Inc (6541)?
The return on equity (ROE) of Tanvex BioPharma Inc is −26.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tanvex BioPharma Inc (6541)?
On an EBIT basis the return on assets of Tanvex BioPharma Inc is −44.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tanvex BioPharma Inc (6541)?
The operating margin of Tanvex BioPharma Inc is −301% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tanvex BioPharma Inc (6541)?
Revenue at Tanvex BioPharma Inc is growing +166% versus a year earlier (3y avg +162%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tanvex BioPharma Inc (6541) generate?
The free cash flow of Tanvex BioPharma Inc is −1.7B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tanvex BioPharma Inc (6541) carry?
The net debt of Tanvex BioPharma Inc is 700M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tanvex BioPharma Inc in the live analysis
One click puts Tanvex BioPharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
